Table 3. Relationship between clinical outcomes and TEG-MAADP defined antiplatelet responsiveness in ticagrelor treated ACS patients (n = 172).
| Clinical outcomes during 3-month follow-up | LTPR MAADP < 31mm (n = 141) |
In therapeutic range 31 ≤ MAADP ≤47 mm (n = 24 ) |
HTPR MAADP > 47 mm (n =7) |
P value |
| Ischemic events | ||||
| Primary events | 0 | 0 | 0 | - |
| Secondary events | 3 (2.13%) | 2 (8.33%) | 2 (28.57%) | 0.03 |
| Bleeding events | ||||
| Major bleeding | 3 (2.13%) | 0 | 0 | - |
| Minor bleeding | 62 (43.97%) | 13 (54.17%) | 3 (42.86%) | 0.65 |
| Adverse events | ||||
| Ticagrelor related dyspnea | 30 (21.28%) | 1 (4.17%) | 0 | 0.02 |
Data are presented as n (%). Primary ischemic endpoints included a composite of cardiac death, non-fatal myocardial infarction and stroke; Secondary efficacy endpoints included a composite of defined or probable stent -thrombosis, coronary revascularization, and re-hospitalization for unstable angina; the major and minor bleeding events are defined according to the updated TIMI criteria. ACS: acute coronary syndrome; HTPR: high on-treatment platelet reactivity; LTPR: low on-treatment platelet reactivity; MAADP: ADP-induced platelet-fibrin clot strength; TEG: thrombelastography; TIMI: thrombolysis in myocardial infarction.